# Types of Diabetes Mellitus

## Classification According to ADA 2024

### Major Categories
1. **Type 1 Diabetes Mellitus (T1DM)**
2. **Type 2 Diabetes Mellitus (T2DM)**
3. **Specific Types of Diabetes Due to Other Causes**
4. **Gestational Diabetes Mellitus (GDM)**

## Type 1 Diabetes Mellitus

### Characteristics
- **Onset**: Usually abrupt, often in childhood/adolescence
- **Pathogenesis**: Autoimmune destruction of β-cells
- **Insulin requirement**: Absolute dependence on exogenous insulin
- **Peak incidence**: 10-14 years (but can occur at any age)

### Epidemiology
- **Global prevalence**: ~10-15% of all diabetes cases
- **Indian prevalence**: ~5-10% of diabetes cases
- **Sex distribution**: Equal in children, slight male predominance in adults
- **Geographic variation**: Higher in northern latitudes

### Clinical Features
- **Classic triad**: Polyuria, polydipsia, polyphagia
- **Acute presentation**: Rapid onset, often with ketoacidosis
- **Body habitus**: Typically non-obese
- **Family history**: Less common than in T2DM

### Autoimmune Markers
- **GAD antibodies**: Present in ~70-80%
- **ICA antibodies**: 70-90% at diagnosis
- **IA-2 antibodies**: 50-60%
- **ZnT8 antibodies**: ~60%
- **C-peptide**: Low or undetectable

### Long-term Complications
- **Similar to T2DM**: Micro- and macrovascular
- **Higher risk**: Acute complications (DKA)
- **CVD risk**: 3-5 times higher than general population
- **Longevity**: Reduced by 10-20 years vs general population

### Special Forms
- **Latent Autoimmune Diabetes of Adults (LADA)**:
  - Adult onset (>35 years)
  - GAD positive, C-peptide present initially
  - Misdiagnosed as T2DM, rapid progression to insulin dependence
  - Represents ~10% of adult-onset "Type 1" diabetes

## Type 2 Diabetes Mellitus

### Characteristics
- **Onset**: Gradual, insidious
- **Pathogenesis**: Insulin resistance with progressive β-cell failure
- **Insulin requirement**: May not need insulin initially
- **Peak incidence**: 45-65 years, but increasingly younger

### Epidemiology
- **Global prevalence**: ~85-90% of all diabetes cases
- **Indian prevalence**: ~90-95% of diabetes cases
- **Asian Indians**: Higher risk at lower BMI
- **Genetic factors**: Strong familial aggregation

### Clinical Features
- **Presentation**: Often asymptomatic initially
- **Obesity**: Central adiposity common
- **Associated conditions**: Hypertension, dyslipidemia, PCOS
- **Family history**: Strong positive history

### Natural History
- **Prediabetes phase**: 5-10 years
- **Insulin resistance phase**: Hyperinsulinemia compensates
- **β-cell failure phase**: Insulin secretion declines
- **Overt diabetes**: Requires treatment

### Clinical Subtypes
- **Metabolic syndrome associated**: Classical T2DM
- **Ketosis-prone**: Rare in Indian population
- **Lean diabetes**: Typically young onset, genetic factors
- **Obesity-associated**: Most common variant

## Specific Types of Diabetes Due to Other Causes

### Monogenic Diabetes
- **MODY (Maturity-Onset Diabetes of the Young)**:
  - **MODY-1**: HNF4A gene, 2-5% of monogenic cases
  - **MODY-2**: Glucokinase gene, 20-30% of cases, mild phenotype
  - **MODY-3**: HNF1A gene, most common (30-40%), sulfonylurea responsive
  - **MODY-4**: IPF1/PDX1 gene
  - **MODY-5**: HNF1B gene, associated with renal anomalies
  - **MODY-6**: NeuroD1 gene

- **Characteristics of MODY**:
  - Age of onset: <25 years (usually childhood to young adulthood)
  - Family history: Autosomal dominant inheritance
  - No obesity, preserved insulin secretion
  - Mild fasting hyperglycemia, often asymptomatio

### Mitochondrial Diabetes
- **Mitochondrial tRNA mutations** (e.g., 3243A>G)
- **Inheritance**: Maternal
- **Features**: Progressive insulin deficiency, deafness, other endocrine defects
- **Prevalence**: Rare (<1% of diabetes cases)

### Pancreatic Disorders
- **Chronic pancreatitis**: Alcohol-induced, hereditary, idiopathic
- **Pancreatectomy**: Surgical removal for tumors or trauma
- **Pancreatic cancer**: Diabetes as paraneoplastic syndrome
- **Cystic fibrosis**: CFTR mutations affecting insulin secretion
- **Hemochromatosis**: Iron overload damaging β-cells

### Endocrinopathies
- **Cushing's syndrome**: Glucocorticoid excess
- **Acromegaly**: GH excess impairing insulin action
- **Pheochromocytoma**: Catecholamine excess
- **Hyperaldosteronism**: Mineralocorticoid excess
- **Glucagonoma**: Excess glucagon inhibiting insulin

### Drug/Toxin Induced
- **Glucocorticoids**: Prednisolone, dexamethasone
- **Chemotherapeutic agents**: Streptozotocin, asparaginase
- **β-blockers**: Impair insulin secretion
- **Thiazides**: Hyperglycemia in 5-10% users
- **Protease inhibitors**: HIV therapy-related
- **Pentamidine**: Used in Pneumocystis treatment

### Genetic Syndromes
- **Down syndrome (Trisomy 21)**
- **Klinefelter syndrome (XXY)**
- **Turner syndrome (XO)**
- **Prader-Willi syndrome**
- **Friedreich's ataxia**

## Gestational Diabetes Mellitus

### Definition
- **Diagnosis**: Glucose intolerance of any degree during pregnancy
- **Import**: Adverse maternal and fetal outcomes
- **Screening**: Between 24-28 weeks gestation

### Epidemiology
- **Prevalence**: 1-14% of pregnancies (varies by population)
- **Indian data**: 10-15% in urban areas
- **Risk factors**: BMI >25, family history, previous GDM

### Clinical Importance
- **Maternal risks**: Preeclampsia, cesarean delivery, future T2DM
- **Fetal risks**: Macrosomia, hypoglycemia, respiratory distress
- **Long-term**: Increased risk of obesity and diabetes in offspring

### Management
- **Dietary therapy**: First line in most cases
- **Insulin**: When diet fails to achieve targets
- **Metformin**: Increasingly used as alternative to insulin
- **Post-delivery**: Screen for diabetes at 6-12 weeks

## Prediabetes and Other Categories

### Prediabetes/Impaired Glucose Tolerance (IGT)
- **IFG**: Fasting glucose 100-125 mg/dL
- **IGT**: 2h PG 140-199 mg/dL
- **Risk**: 5-10% annual progression to diabetes
- **Regression possible**: With lifestyle intervention

### Diabetes in Special Populations

#### Pediatric Diabetes
- **Type 1**: >95% of pediatric diabetes
- **Type 2**: Increasing in obese adolescents
- **Monogenic**: Neonatal diabetes, MODY
- **Cystic fibrosis related**: Rare

#### Geriatric Diabetes
- **Prevalence**: Higher with age
- **Treatment**: Careful due to comorbidities
- **Goals**: Less stringent HbA1c targets
- **Management**: Focus on hypoglycemia prevention

#### Diabetes in Neurological Disorders
- **Stiff person syndrome**: GAD antibodies
- **Multiple sclerosis**: Increased risk
- **Polycystic ovary syndrome (PCOS)**: 50% have insulin resistance

## Diagnostic Distinction

### Key Differentiating Features

| Feature | Type 1 DM | Type 2 DM | MODY | LADA |
|---------|-----------|-----------|------|------|
| Age at onset | <30 years | >40 years | <25 years | >35 years |
| BMI | Normal | Often elevated | Normal | Variable |
| Autoantibodies | +++ | - | - | +++ |
| C-peptide at diagnosis | Low | Normal/high | Normal | Low |
| Family history | Variable | Strong | Strong | Variable |
| Ketosis | Common | Rare | Rare | Possible |
| Insulin response to SU | Poor | Good | Good | Poor |

## Learning Objectives
- Classify different types of diabetes mellitus
- Understand characteristics of Type 1 and Type 2 DM
- Recognize specific types due to other causes
- Differentiate between diabetes types clinically
- Apply appropriate treatment modalities
- Understand natural history and progression
